Scholar Rock (SRRK) Competitors

Scholar Rock logo
$44.54 +1.33 (+3.08%)
Closing price 04:00 PM Eastern
Extended Trading
$44.49 -0.05 (-0.11%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SRRK vs. ALNY, EXEL, ASND, BBIO, and HALO

Should you buy Scholar Rock stock or one of its competitors? Scholar Rock's main competitors and comparable companies include Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Scholar Rock compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Alnylam Pharmaceuticals has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alnylam Pharmaceuticals$3.71B5.95$313.75M$19.268.57
Scholar RockN/AN/A-$377.94M-$3.36N/A

Alnylam Pharmaceuticals has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Alnylam Pharmaceuticals presently has a consensus target price of $305.86, suggesting a potential upside of 85.33%. Scholar Rock has a consensus target price of $67.67, suggesting a potential upside of 56.60%. Given Alnylam Pharmaceuticals' higher probable upside, equities research analysts clearly believe Alnylam Pharmaceuticals is more favorable than Scholar Rock.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals
0 Sell rating(s)
10 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.65
Scholar Rock
2 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
2.82

Alnylam Pharmaceuticals has a net margin of 52.85% compared to Scholar Rock's net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 155.33% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals52.85% 155.33% 44.81%
Scholar Rock N/A -175.27%-86.66%

In the previous week, Scholar Rock had 17 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 33 mentions for Scholar Rock and 16 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.44 beat Scholar Rock's score of 0.39 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alnylam Pharmaceuticals
2 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Scholar Rock
5 Very Positive mention(s)
2 Positive mention(s)
11 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 10.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Alnylam Pharmaceuticals beats Scholar Rock on 11 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Exelixis?

Scholar Rock (NASDAQ:SRRK) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

In the previous week, Scholar Rock had 20 more articles in the media than Exelixis. MarketBeat recorded 33 mentions for Scholar Rock and 13 mentions for Exelixis. Exelixis' average media sentiment score of 0.46 beat Scholar Rock's score of 0.39 indicating that Exelixis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scholar Rock
5 Very Positive mention(s)
2 Positive mention(s)
11 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Exelixis
4 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Scholar Rock has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

Exelixis has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scholar RockN/AN/A-$377.94M-$3.36N/A
Exelixis$2.50B6.74$782.57M$3.3420.66

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Comparatively, 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Exelixis has a net margin of 35.45% compared to Scholar Rock's net margin of 0.00%. Exelixis' return on equity of 45.54% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Scholar RockN/A -175.27% -86.66%
Exelixis 35.45%45.54%33.90%

Scholar Rock presently has a consensus price target of $67.67, suggesting a potential upside of 56.60%. Exelixis has a consensus price target of $58.62, suggesting a potential downside of 15.05%. Given Scholar Rock's stronger consensus rating and higher possible upside, equities analysts clearly believe Scholar Rock is more favorable than Exelixis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scholar Rock
2 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
2.82
Exelixis
1 Sell rating(s)
10 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.39

Summary

Scholar Rock and Exelixis tied by winning 8 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Ascendis Pharma A/S?

Scholar Rock (NASDAQ:SRRK) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Ascendis Pharma A/S has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scholar RockN/AN/A-$377.94M-$3.36N/A
Ascendis Pharma A/S$814.57M21.09-$258M$15.3018.00

In the previous week, Scholar Rock had 4 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 33 mentions for Scholar Rock and 29 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.69 beat Scholar Rock's score of 0.39 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scholar Rock
5 Very Positive mention(s)
2 Positive mention(s)
11 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ascendis Pharma A/S
7 Very Positive mention(s)
4 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Scholar Rock has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

Scholar Rock currently has a consensus price target of $67.67, suggesting a potential upside of 56.60%. Ascendis Pharma A/S has a consensus price target of $313.52, suggesting a potential upside of 13.85%. Given Scholar Rock's higher probable upside, analysts clearly believe Scholar Rock is more favorable than Ascendis Pharma A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scholar Rock
2 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
2.82
Ascendis Pharma A/S
0 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.90

91.1% of Scholar Rock shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ascendis Pharma A/S has a net margin of 73.26% compared to Scholar Rock's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.47% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Scholar RockN/A -175.27% -86.66%
Ascendis Pharma A/S 73.26%32.47%13.26%

Summary

Ascendis Pharma A/S beats Scholar Rock on 11 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to BridgeBio Pharma?

Scholar Rock (NASDAQ:SRRK) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Scholar Rock has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scholar RockN/AN/A-$377.94M-$3.36N/A
BridgeBio Pharma$945.54M16.13-$724.93M-$3.04N/A

Scholar Rock has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -59.84%. BridgeBio Pharma's return on equity of 0.00% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Scholar RockN/A -175.27% -86.66%
BridgeBio Pharma -59.84%N/A -39.81%

Scholar Rock currently has a consensus target price of $67.67, suggesting a potential upside of 56.60%. BridgeBio Pharma has a consensus target price of $104.42, suggesting a potential upside of 33.36%. Given Scholar Rock's stronger consensus rating and higher possible upside, equities research analysts clearly believe Scholar Rock is more favorable than BridgeBio Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scholar Rock
2 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
2.82
BridgeBio Pharma
1 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.82

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Scholar Rock had 21 more articles in the media than BridgeBio Pharma. MarketBeat recorded 33 mentions for Scholar Rock and 12 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.99 beat Scholar Rock's score of 0.39 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scholar Rock
5 Very Positive mention(s)
2 Positive mention(s)
11 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
BridgeBio Pharma
3 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Scholar Rock has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Summary

BridgeBio Pharma beats Scholar Rock on 9 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Halozyme Therapeutics?

Scholar Rock (NASDAQ:SRRK) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

In the previous week, Scholar Rock had 21 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 33 mentions for Scholar Rock and 12 mentions for Halozyme Therapeutics. Scholar Rock's average media sentiment score of 0.39 beat Halozyme Therapeutics' score of 0.13 indicating that Scholar Rock is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scholar Rock
5 Very Positive mention(s)
2 Positive mention(s)
11 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Halozyme Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Halozyme Therapeutics has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scholar RockN/AN/A-$377.94M-$3.36N/A
Halozyme Therapeutics$1.40B8.19$316.89M$3.9325.51

Scholar Rock presently has a consensus price target of $67.67, indicating a potential upside of 56.60%. Halozyme Therapeutics has a consensus price target of $108.18, indicating a potential upside of 7.89%. Given Scholar Rock's stronger consensus rating and higher probable upside, equities research analysts clearly believe Scholar Rock is more favorable than Halozyme Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scholar Rock
2 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
3 Strong Buy rating(s)
2.82
Halozyme Therapeutics
1 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.46

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Scholar Rock has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Halozyme Therapeutics has a net margin of 26.93% compared to Scholar Rock's net margin of 0.00%. Halozyme Therapeutics' return on equity of 751.81% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Scholar RockN/A -175.27% -86.66%
Halozyme Therapeutics 26.93%751.81%23.84%

Summary

Halozyme Therapeutics beats Scholar Rock on 9 of the 16 factors compared between the two stocks.

Get Scholar Rock News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRRK vs. The Competition

MetricScholar RockBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$5.27B$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E Ratio-13.2626.5532.9127.37
Price / SalesN/A16.058.595.73
Price / CashN/A26.3721.9322.50
Price / Book32.284.074.403.70
Net Income-$377.94M-$22.86M$3.52B$392.17M
7 Day Performance-13.60%-7.26%-5.34%-4.53%
1 Month Performance11.63%-4.96%-3.61%-5.86%
1 Year Performance19.06%-2.87%0.01%-7.78%

Scholar Rock Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRRK
Scholar Rock
3.2955 of 5 stars
$44.54
+3.1%
$67.67
+51.9%
+15.5%$5.27BN/AN/A289
ALNY
Alnylam Pharmaceuticals
4.8593 of 5 stars
$156.61
+0.4%
$305.86
+95.3%
-63.3%$20.89B$5.01B8.132,770
EXEL
Exelixis
2.2728 of 5 stars
$71.74
+3.1%
$58.85
-18.0%
+65.7%$17.75B$2.32B21.481,077
ASND
Ascendis Pharma A/S
4.2447 of 5 stars
$259.85
+1.2%
$305.95
+17.7%
+34.7%$16.09B$814.57M20.161,189
BBIO
BridgeBio Pharma
3.5932 of 5 stars
$77.93
+4.9%
$104.26
+33.8%
+17.9%$15.17B$502.08MN/A839

Related Companies and Tools


This page (NASDAQ:SRRK) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners